All In Biotech

Company · DSNKY

Daiichi Sankyo

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Daiichi Sankyo.

Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

7

6 still marketed

Novel approvals

6

Approvals since 2021

21

Originals and new uses

Phase 3 trials

97

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Datroway new use Priority reviewMay 22, 2026
  • Enhertu new use Breakthrough therapyPriority reviewOrphanMay 15, 2026
  • Enhertu new use OrphanMay 15, 2026
  • Enhertu new use OrphanApr 27, 2026
  • Enhertu new use Breakthrough therapyPriority reviewOrphanDec 15, 2025
  • Datroway approved NovelBreakthrough therapyAccelerated approvalPriority reviewJun 23, 2025
  • Enhertu new use Breakthrough therapyPriority reviewOrphanJan 27, 2025
  • Datroway approved NovelJan 17, 2025
  • Enhertu new use Breakthrough therapyPriority reviewOrphanApr 5, 2024
  • Enhertu new use OrphanFeb 15, 2024

Drugs in development (11)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • I-DXdDS-7300a, MK-2400Phase 317 trials

    Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma

  • R-DXdDS 6000a, MK-5909Phase 310 trials

    Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

  • OlomorasibLY3537982Phase 36 trials

    Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis

  • AmrubicinJapan onlyPhase 34 trials

    Gilead Sciences · Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC), Small Cell Lung Cancer (SCLC)

  • SafusidenibDS-1001b, AB-218Phase 34 trials

    Nuvation Bio Inc. · Oligodendroglioma, Glioma, IDH1-mutant Glioma

  • valemetostat tosylateDS-3201bPhase 23 trials

    Daiichi Sankyo · Non-small Cell Lung Cancer, Lung Cancer, Relapsed/Refractory Peripheral T-Cell Lymphoma

  • DS-3939aPhase 22 trials

    Daiichi Sankyo · Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

  • DS-1103aPhase 21 trial

    Daiichi Sankyo · Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

  • DS-7011aPhase 21 trial

    Daiichi Sankyo · Systemic Lupus Erythematosus

  • DS3790aPhase 21 trial

    Daiichi Sankyo · Hematological Malignancies, B-cell Non-Hodgkin Lymphoma

  • RenadirsenDS-5141bPhase 21 trial

    Daiichi Sankyo · Duchenne Muscular Dystrophy

Recruiting Phase 3 trials

Largest first.

Marketed drugs (6)

Newest FDA action first.

  • Datroway Datopotamab Deruxtecan-Dlnk · 2025
  • Enhertu Fam-Trastuzumab Deruxtecan-Nxki · 2019
  • Vanflyta Quizartinib Dihydrochloride · 2023
  • Turalio Pexidartinib Hydrochloride · 2019
  • Datroway Datopotamab Deruxtecan-Dlnk · 2025
  • Savaysa Edoxaban Tosylate · 2015

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.